DM-CHOC-PEN

Drug Profile

DM-CHOC-PEN

Alternative Names: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine; Penclomidine derivative

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dekk-Tec
  • Class Antineoplastics; Carbonates; Picolines
  • Mechanism of Action Alkylating agents; Cell cycle modulators; Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Brain cancer; Brain metastases
  • Phase I Cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 13 Dec 2017 DM-CHOC-PEN receives Orphan Drug status for Non-small cell lung cancer involving brain metastasis (Metastatic disease) in USA (NCT03371004)
  • 01 Apr 2017 Efficacy data from preclinical, phase I, and phase II trials in Solid tumours (including brain cancer/metastases)presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR - 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top